RxSight, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXST research report →
Companywww.rxsight.com
RxSight, Inc. , a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
- CEO
- Ronald Kurtz
- IPO
- 2021
- Employees
- 498
- HQ
- Aliso Viejo, CA, US
Price Chart
Valuation
- Market Cap
- $255.00M
- P/E
- -5.46
- P/S
- 2.00
- P/B
- 0.95
- EV/EBITDA
- -4.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.02%
- Op Margin
- -43.42%
- Net Margin
- -36.58%
- ROE
- -17.01%
- ROIC
- -19.90%
Growth & Income
- Revenue
- $134.48M · -3.89%
- Net Income
- $-38,943,000 · -41.84%
- EPS
- $-0.95 · -33.80%
- Op Income
- $-48,190,000
- FCF YoY
- 13.60%
Performance & Tape
- 52W High
- $16.68
- 52W Low
- $5.30
- 50D MA
- $6.78
- 200D MA
- $8.68
- Beta
- 1.24
- Avg Volume
- 738.93K
Get TickerSpark's AI analysis on RXST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Goldshleger Ilya | other | 12,489 |
| Apr 17, 26 | Goldshleger Ilya | other | 12,489 |
| Feb 28, 26 | Wilterding Mark | other | 20,441 |
| Feb 28, 26 | Wilterding Mark | other | 20,441 |
| Feb 28, 26 | Wilterding Mark | other | 8,068 |
| Feb 27, 26 | Gaines Scott | other | 32,218 |
| Feb 28, 26 | Gaines Scott | other | 6,261 |
| Feb 28, 26 | Gaines Scott | other | 2,580 |
| Feb 28, 26 | Gaines Scott | other | 1,657 |
| Feb 28, 26 | Gaines Scott | other | 1,250 |
Our RXST Coverage
We haven't published any research on RXST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RXST Report →